Physician profile
Michael U Levinson
NPI 1306876883
$60,974.41
in general payments reported to CMS, 2019-2025
32 companies · $3,866 in 2025
The $3,866 reported for 2025 was more than what 94% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,601 · 2020: $8,736 · 2021: $7,635 · 2022: $18K · 2023: $12K · 2024: $3,529 · 2025: $3,866.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $6,825 · Travel and Lodging: $1,044 · Education: $1.68.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,508.69 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $6,825.00 |
| Travel and Lodging | $1,043.66 |
| Education | $1.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $17,838.15 | 2021-2025 | |
| Allergan, INC. | $9,698.46 | 2019-2020 | |
| Eisai INC. | $7,189.60 | 2020-2022 | |
| Sunovion Pharmaceuticals INC. | $4,308.19 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $2,979.17 | 2020-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $2,655.96 | 2019-2025 | Ingrezza |
| Alkermes, INC. | $2,482.71 | 2019-2025 | Aristada, Lybalvi |
| Lundbeck LLC | $2,216.89 | 2019-2025 | Rexulti, Abilify Asimtufii |
| Takeda Pharmaceuticals U.S.A., INC. | $1,653.70 | 2019-2025 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $1,637.12 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Vanda Pharmaceuticals INC. | $1,355.82 | 2019-2025 | Fanapt, Hetlioz |
| Teva Pharmaceuticals USA, INC. | $1,082.00 | 2019-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Axsome Therapeutics, INC. | $737.78 | 2023-2025 | Auvelity |
| Indivior INC. | $669.92 | 2019-2023 | Perseris |
| E.R. Squibb & Sons, L.L.C. | $651.75 | 2024-2025 | Cobenfy |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $591.68 | 2022-2024 | Quviviq |
| Corium, LLC | $552.57 | 2022-2024 | Azstarys |
| Jazz Pharmaceuticals INC. | $468.46 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $394.50 | 2020-2024 | Invega Sustenna, Invega, Spravato |
| Merck Sharp & Dohme LLC | $295.57 | 2020-2023 | Belsomra |
| Bausch Health US, LLC | $287.27 | 2019-2022 | |
| Adlon Therapeutics L.P. | $265.30 | 2019-2021 | |
| Almatica Pharma LLC | $235.56 | 2021-2025 | Loreev Xr |
| Shire North American Group INC | $209.40 | 2019 | |
| Ironshore Pharmaceuticals INC. | $132.53 | 2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $101.17 | 2022 | |
| Alfasigma USA, INC. | $83.15 | 2020-2022 | |
| Noven Therapeutics, LLC | $64.84 | 2024 | Xelstrym |
| Sumitomo Pharma America, INC. | $58.27 | 2023 | Latuda |
| Pfizer INC. | $48.32 | 2023 | |
| Avanir Pharmaceuticals, INC. | $28.60 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Levinson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.